Over the last years it has started a real revolution in the treatment of chronic hepatitis C. This
occurred for the availability of direct-acting antiviral agents that allow to reach sustained …

Background With the explosion of newly available direct acting antiviral (DAA) Hepatitis C
virus (HCV) treatments that demonstrate 95% sustained virologic response (SVR) rates …

Background. Hepatocellular carcinoma is one of the most common and lethal malignant
tumors worldwide. Over the past 15 years, the incidence of HCC has more than doubled …

Hepatocellular carcinoma (HCC) is the most common type of liver cancer. The main risk
factors for HCC are alcoholism, hepatitis B virus, hepatitis C virus, nonalcoholic …

Background. Carbohydrate 19.9 antigen (CA19. 9) has been used in the diagnosis and
followup of gastrointestinal tumours. The aim of this prospective longitudinal study was the …

Background. Hepatocellular carcinoma is a major health problem worldwide and the third
most common cause of cancer‐related death. HCC treatment decisions are complex and …

Background Benign liver tumors are common. They do not spread to other areas of the body,
and they usually do not pose a serious health risk. In fact, in most cases, benign liver tumors …

Combined pegylated interferon (PegIFN) and ribavirin represents the standard therapy for
patients with chronic hepatitis C (CHC), which allows for sustained viral response (SVR) in …

Anaemia is a common complication of antiviral therapy for chronic hepatitis C virus (HCV)
infection that necessitates dose reductions or therapy discontinuation. Administration of …

OBJECTIVE: To review the literature regarding current strategies for the management of
anemia associated with treatment for chronic viral hepatitis C (HCV) in adults. DATA …